RPT-DEALTALK-Debt-laden Valeant faces tough choices in asset sales

NEW YORK, April 19 (Reuters) - As Valeant Pharmaceuticals

considers a multibillion-dollar auction to pare down $30 billion

in debt, its challenge will be choosing which assets to sell

without...

Read more